Art

J-GLOBAL ID：201902216975459383   Reference number：19A1130585

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

EGFR陽性進行性非扁平上皮非小細胞肺癌(NEJ026)患者におけるエルロチニブ+ベバシズマブ対エルロチニブ単独: オープンラベル無作為化多施設第3相試験の中間分析【JST・京大機械翻訳】

Author (25)： Saito Haruhiro (Kanagawa Cancer Center, Yokohama, Japan) ,  Fukuhara Tatsuro (Miyagi Cancer Center, Natori, Japan) ,  Furuya Naoki (St Marianna University School of Medicine, Kawasaki, Japan) ,  Watanabe Kana (Miyagi Cancer Center, Natori, Japan) ,  Sugawara Shunichi (Sendai Kousei Hospital, Sendai, Japan) ,  Iwasawa Shunichiro (Chiba University, Chiba, Japan) ,  Tsunezuka Yoshio (Ishikawa Prefectural Central Hospital, Kanazawa, Japan) ,  Yamaguchi Ou (Saitama Medical University, Saitama, Japan) ,  Okada Morihito (Hiroshima University Hospital, Hiroshima, Japan) ,  Yoshimori Kozo (Fukujuji Hospital, Tokyo, Japan) ,  Nakachi Ichiro (Saiseikai Utsunomiya Hospital, Utsunomiya, Japan) ,  Gemma Akihiko (Nippon Medical School, Tokyo, Japan) ,  Azuma Koichi (Kurume University, Kurume, Japan) ,  Kurimoto Futoshi (Saitama Cancer Center, Saitama, Japan) ,  Tsubata Yukari (Shimane University, Shimane, Japan) ,  Fujita Yuka (National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan) ,  Nagashima Hiromi (Iwate Medical University School of Medicine, Morioka, Japan) ,  Asai Gyo (Aichi Cancer Center Aichi Hospital, Okazaki, Japan) ,  Watanabe Satoshi (Niigata University Medical and Dental Hospital, Niigata, Japan) ,  Miyazaki Masaki (Suita Municipal Hospital, Osaka, Japan) ,  Hagiwara Koichi (Jichi Medical University, Shimotsuke, Japan) ,  Nukiwa Toshihiro (Tohoku University, Miyagi, Japan) ,  Morita Satoshi (Kyoto University, Kyoto, Japan) ,  Kobayashi Kunihiko (Saitama Medical University, Saitama, Japan) ,  Maemondo Makoto (Iwate Medical University School of Medicine, Morioka, Japan)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 20  Issue： 5  Page： 625-635  Publication year： 2019 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Resistance to first-generation...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1130585&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： drug therapy ,  population(statistics) ,  mutation ,  evaluation criterion ,  safety ,  *EGF receptor ,  recurrence ,  *non-small cell lung cancer ,  effectiveness ,  *phase 3 study ,  quality of life ,  combination therapy ,  enzyme inhibitor
Semi thesaurus term： 有害事象 ,  *ベバシズマブ , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Substance index (1)： Erlotinib

Terms in the title (9)： EGFR ,  非扁平上皮非小細胞肺癌 ,  患者 ,  エルロチニブ ,  ベバシズマブ ,  ラベル ,  施設 ,  第3相試験 ,  分析